Understanding the Gender Disparity: Why Liver Cancer is More Common in Men than Women

Study Investigates Gender Disparity in Liver Cancer Development

Overview of Liver Cancer Statistics

A recent study published in the Journal of Experimental Medicine examined the molecular factors contributing to the gender disparity in liver cancer incidence. According to research from the International Agency for Research on Cancer, liver cancer ranks as the fourth deadliest cancer globally. The most prevalent type, hepatocellular carcinoma (HCC), primarily affects individuals with obesity and is notably more common in men. HCC incidence is nearly twice as high in men compared to women, making it the second-leading cause of cancer-related deaths among men. Despite its significant prevalence, the underlying molecular factors responsible for this gender difference remain largely unclear.

Research Focus on Adiponectin

To address this gap, a team of Spanish researchers explored the connection between adiponectin—a hormone produced by adipose (fat) tissue—sex hormones, and liver cancer development. The study’s authors were particularly interested in adiponectin due to its declining levels in men after puberty, unlike in women, and its association with type 2 diabetes and obesity. Dr. Sabio, the study’s lead researcher, noted in a press release that these populations exhibit higher liver cancer rates, prompting the investigation into whether adiponectin correlates with liver cancer occurrence and if the disparity in its levels between genders could explain the different HCC incidences.

Findings on Adiponectin Levels and Protection Against HCC

The researchers confirmed that adiponectin levels are significantly higher in women than in men. This observation was consistent in mouse models, which showed that female mice lacking adiponectin developed HCC at rates comparable to male mice. These findings suggest that elevated adiponectin levels may provide protective effects against HCC in women.

Exploring Mechanisms Behind Adiponectin Variation

The study further investigated the reasons for the differing adiponectin levels between genders. The researchers identified the enzyme JNK, a crucial protein involved in regulating liver metabolism, as a key factor influencing adiponectin blood levels in both mouse and rat models. They discovered that testosterone regulates JNK, leading to higher JNK activity in the presence of elevated testosterone levels. This increased activity subsequently inhibits adiponectin release into the bloodstream.

Conclusions and Future Implications

The results of this study reveal two critical insights:
1. A molecular connection exists between adipose tissue (specifically adiponectin and JNK) and liver cancer.
2. The higher prevalence of liver cancer in men may be linked to the regulation of adiponectin levels by testosterone.

Dr. Sabio concluded that these findings could pave the way for new approaches to combat HCC, which currently lacks effective treatments. Potential strategies may include utilizing adiponectin directly or employing metformin, a diabetes medication targeting the same anticancer protein as adiponectin.

References

Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. (2019). http://doi.org/10.1084/jem.20181288
IOS Press. (2019, February 21). Adiponectin, the hormone that protects women against liver cancer. EurekAlert! Retrieved April 3, 2019 from https://www.eurekalert.org/pub_releases/2019-04/cndi-ath032719.php